Comparative Pharmacology
Head-to-head clinical analysis: CHLOROTHIAZIDE SODIUM versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 100 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROTHIAZIDE SODIUM versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 100 50.
CHLOROTHIAZIDE SODIUM vs HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in distal convoluted tubule of nephron, reducing sodium reabsorption and promoting diuresis.
Hydralazine: Direct vasodilation of arterioles via unknown mechanism, possibly involving nitric oxide. Hydrochlorothiazide: Thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
500 mg to 1 g orally or intravenously once or twice daily.
1 tablet (hydralazine 100 mg / hydrochlorothiazide 50 mg) orally once daily. Maximum: 1 tablet daily. Titrate from lower doses of individual components.
None Documented
None Documented
Terminal elimination half-life is 45–120 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Hydralazine: 2-8 hours (prolonged in renal impairment); Hydrochlorothiazide: 6-15 hours (increased in renal impairment)
Primarily renal excretion via tubular secretion; approximately 95% of absorbed dose excreted unchanged in urine within 24 hours, with less than 5% eliminated via bile/feces.
Hydralazine: 90% renal metabolites, 10% feces; Hydrochlorothiazide: >95% renal (tubular secretion) as unchanged drug
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic